| DIRECT COMPETITOR COMPARISON | |
| MTEX | NATR | Pvt1 | USNA | Industry | | Market Cap: | 75.20M | 112.45M | N/A | 491.14M | 93.02M | | Employees: | 540 | 1,183 | N/A | 948 | 280 | | Qtrly Rev Growth (yoy): | -8.60% | -7.40% | N/A | 3.30% | 9.60% | | Revenue (ttm): | 296.12M | 341.31M | N/A | 431.21M | 71.35M | | Gross Margin (ttm): | 33.73% | 79.68% | N/A | 79.25% | 52.09% | | EBITDA (ttm): | -13.62M | 9.15M | N/A | 57.19M | 220.78K | | Oper Margins (ttm): | -8.80% | 1.37% | N/A | 11.61% | 8.30% | | Net Income (ttm): | -18.90M | 1.62M | N/A | 27.84M | N/A | | EPS (ttm): | -0.714 | 0.105 | N/A | 1.800 | N/A | | P/E (ttm): | N/A | 69.05 | N/A | 17.83 | 15.93 | | PEG (5 yr expected): | N/A | N/A | N/A | 0.94 | 0.97 | | P/S (ttm): | 0.25 | 0.33 | N/A | 1.14 | 1.17 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.35 | 0.00% | 57.03B | 12.29 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.94 | 0.00% | 13.57B | 15.71 | | Genzyme Corp. | GENZ | 50.70 | 0.00% | 13.45B | 28.91 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.11 | 0.00% | 41.50B | 17.83 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.78 | 0.00% | 8.88B | 1015.92 | | Teva Pharmaceutical Industries Limited | TEVA | 52.79 | 0.00% | 46.51B | 48.30 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.09 | 0.00% | 3.94B | 19.12 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.83 | 0.00% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.87 | 0.00% | 5.46B | 109.63 | | Pfizer Inc. | PFE | 18.17 | 0.00% | 146.62B | 15.09 | | Johnson & Johnson | JNJ | 62.84 | 0.00% | 173.38B | 13.72 | | GlaxoSmithKline plc | GSK | 41.47 | 0.00% | 105.13B | 13.17 | | Sanofi-Aventis | SNY | 37.96 | 0.00% | 99.12B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.60 | 0.00% | 126.28B | 16.65 | | RHHBY.PK | 40.92 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 44.83 | 0.00% | 65.00B | 9.00 | | Abbott Laboratories | ABT | 54.49 | 0.00% | 84.28B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 25.31 | 0.00% | 50.14B | 13.09 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | USNA | | Investors Find Fat Gains in Nutrition Stocks
Tue, Nov 17 -
Indie Research | | • | USNA | | USANA HEALTH SCIENCES INC Financials
Sat, Nov 14 -
EDGAR Online Financials | | • | NATR | | NATURES SUNSHINE PRODUCTS INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | NATR | | NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
Thu, Nov 12 -
EDGAR Online | | • | USNA | | USANA HEALTH SCIENCES INC Files SEC form 10-Q, Quarterly Report
Tue, Nov 10 -
EDGAR Online | | • | NATR | | NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
Mon, Nov 9 -
EDGAR Online | | • | NATR | | NATURES SUNSHINE PRODUCTS INC Files SEC form 10-Q, Quarterly Report
Mon, Nov 9 -
EDGAR Online | | • | NATR | | Nature's Sunshine Products Reports Third Quarter Operating Results
Fri, Nov 6 -
Business Wire | | • | USNA | | USANA Health Sciences Launches Vitamin D Supplement
Mon, Nov 2 -
Business Wire | | • | USNA | | CEO Interview: Mannatech, Inc. - Wayne L. Badovinus
Mon, Nov 2 -
Wall Street Transcript | | | All Headlines for these symbols... |
|
|
|
0.34% Nasdaq 0.00%
Competitors
